Cargando…
Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study
OBJECTIVE: Hepatic steatosis is associated with increased surgical complications in bariatric surgery patients. We aimed to evaluate the effect of phentermine in reducing hepatic steatosis, adipose tissue, and surgical complications in patients undergoing bariatric surgery. METHODS: This was a two-a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275005/ https://www.ncbi.nlm.nih.gov/pubmed/35526530 http://dx.doi.org/10.1159/000524805 |
_version_ | 1784745403584872448 |
---|---|
author | Pérez-Cruz, Elizabeth Guevara-Cruz, Martha Ortiz-Gutiérrez, Salvador Luna-Camacho, Yuritzy Guzmán-Aguilar, Rafael Briceño-Sáenz, Giuseppe González-Salazar, Luis Flores-López, Adriana |
author_facet | Pérez-Cruz, Elizabeth Guevara-Cruz, Martha Ortiz-Gutiérrez, Salvador Luna-Camacho, Yuritzy Guzmán-Aguilar, Rafael Briceño-Sáenz, Giuseppe González-Salazar, Luis Flores-López, Adriana |
author_sort | Pérez-Cruz, Elizabeth |
collection | PubMed |
description | OBJECTIVE: Hepatic steatosis is associated with increased surgical complications in bariatric surgery patients. We aimed to evaluate the effect of phentermine in reducing hepatic steatosis, adipose tissue, and surgical complications in patients undergoing bariatric surgery. METHODS: This was a two-arm, double-blind, randomized, controlled pilot trial of 64 adult subjects with BMI >35 kg/m<sup>2</sup> selected for bariatric surgery randomized into phentermine group (15 mg once daily) or placebo group for 8 weeks. Both groups adhered to a hypocaloric diet (500 calories/day) and an individualized exercise program. The primary endpoint was reducing the frequency of hepatic steatosis measured by ultrasound and reducing adipose tissue through fat mass in total kilograms or percentage. Key secondary points were the prevalence of surgical complications. Baseline and final biochemical parameters and blood pressure too were assessments. RESULTS: In the phentermine group, the frequency of hepatic steatosis decreased by 19%, and the percentage of patients with a normal ultrasound increased from 9% to 28% (p = 0.05). Likewise, the decrease in fat mass in kilograms was more significant in the phentermine group (56.1 kg vs. 51.8 kg, p = 0.02). A significant reduction in the HOMA-IR index was observed regardless of weight loss. No differences in surgical complications were observed between groups. Phentermine was well-tolerated; no differences were observed in the frequency of adverse events between the groups. CONCLUSIONS: Phentermine decreased the proportion of individuals with hepatic steatosis by 19% and promoted a more significant fat mass loss in kilograms among candidates for bariatric surgery. |
format | Online Article Text |
id | pubmed-9275005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-92750052022-08-16 Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study Pérez-Cruz, Elizabeth Guevara-Cruz, Martha Ortiz-Gutiérrez, Salvador Luna-Camacho, Yuritzy Guzmán-Aguilar, Rafael Briceño-Sáenz, Giuseppe González-Salazar, Luis Flores-López, Adriana Med Princ Pract Original Paper OBJECTIVE: Hepatic steatosis is associated with increased surgical complications in bariatric surgery patients. We aimed to evaluate the effect of phentermine in reducing hepatic steatosis, adipose tissue, and surgical complications in patients undergoing bariatric surgery. METHODS: This was a two-arm, double-blind, randomized, controlled pilot trial of 64 adult subjects with BMI >35 kg/m<sup>2</sup> selected for bariatric surgery randomized into phentermine group (15 mg once daily) or placebo group for 8 weeks. Both groups adhered to a hypocaloric diet (500 calories/day) and an individualized exercise program. The primary endpoint was reducing the frequency of hepatic steatosis measured by ultrasound and reducing adipose tissue through fat mass in total kilograms or percentage. Key secondary points were the prevalence of surgical complications. Baseline and final biochemical parameters and blood pressure too were assessments. RESULTS: In the phentermine group, the frequency of hepatic steatosis decreased by 19%, and the percentage of patients with a normal ultrasound increased from 9% to 28% (p = 0.05). Likewise, the decrease in fat mass in kilograms was more significant in the phentermine group (56.1 kg vs. 51.8 kg, p = 0.02). A significant reduction in the HOMA-IR index was observed regardless of weight loss. No differences in surgical complications were observed between groups. Phentermine was well-tolerated; no differences were observed in the frequency of adverse events between the groups. CONCLUSIONS: Phentermine decreased the proportion of individuals with hepatic steatosis by 19% and promoted a more significant fat mass loss in kilograms among candidates for bariatric surgery. S. Karger AG 2022-05-06 /pmc/articles/PMC9275005/ /pubmed/35526530 http://dx.doi.org/10.1159/000524805 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Original Paper Pérez-Cruz, Elizabeth Guevara-Cruz, Martha Ortiz-Gutiérrez, Salvador Luna-Camacho, Yuritzy Guzmán-Aguilar, Rafael Briceño-Sáenz, Giuseppe González-Salazar, Luis Flores-López, Adriana Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title | Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title_full | Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title_fullStr | Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title_full_unstemmed | Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title_short | Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study |
title_sort | effect of phentermine on hepatic steatosis in bariatric surgery: a pilot study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275005/ https://www.ncbi.nlm.nih.gov/pubmed/35526530 http://dx.doi.org/10.1159/000524805 |
work_keys_str_mv | AT perezcruzelizabeth effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT guevaracruzmartha effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT ortizgutierrezsalvador effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT lunacamachoyuritzy effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT guzmanaguilarrafael effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT bricenosaenzgiuseppe effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT gonzalezsalazarluis effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy AT floreslopezadriana effectofphentermineonhepaticsteatosisinbariatricsurgeryapilotstudy |